Alexander Gutmans

Alexander Gutmans

Dr. iur., LL.M., Avvocato e Notaio




Telefono diretto: +41 58 658 14 51

Curriculum Vitae

PDF download

Alexander Gutmans is a partner at Walder Wyss since 2014. He advises national and international clients in the fields of commercial and corporate law, mergers & acquisitions, private equity, venture capital and financings as well as in the field of health care and life sciences in contractual and regulatory matters. As a notary of the canton Basel-Stadt he accompanies his clients in commercial register and real estate register transactions as well as German notarisations. Alexander Gutmans is also active as board member.

Born in 1967, Alexander Gutmans studied at the university of Basel (lic. iur. 1990; Dr. iur. 1995) and Lausanne an received a master’s degree from Yale Law School (LL.M. 1996). In 1993 Alexander Gutmans was admitted as attorney at law and in 2002 as notary. He started his professional career as legal counsel at Sandoz AG and after an assignment as foreign associate with an American law firm in New York he worked during 15 years as a lawyer for a leading Swiss law firm with offices in Basel, Bern and Zurich, during the last 11 years as a partner.

Alexander Gutmans‘ professional work languages are German and English. He also speaks French.

SixPeaks Bio AG debuts with USD 110 million in Funding

Walder Wyss berät P&I Personal & Informatik AG beim Verkauf der Mirus Software AG an Alpha VCX

Axalta Coating Systems Group acquires André Koch AG

Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma

Nouscom Raises €67.5m ($72m) in Oversubscribed Series C Financing Round

Syz Capital und Saturnus Capital investieren in Capture Media

Zusammenschluss von SETEX und Datatex mit Elvaston

CONVOTIS startet mit der Übernahme der JMC Gruppe als Plattformunternehmen in den Schweizer IT Markt und stärkt seine Positionierung im Segment der Managed Services und digitalen Plattformlösungen.

LimmaTech Biologics Raises $37 Million Series A to Advance Its Pipeline of Vaccines Against Multidrug-Resistant Bacterial Infections

IFLR 1000 Rankings - Walder Wyss as a top-performing law firm ranked

Pierre Fabre Laboratories acquires Vertical Bio AG

Das Familienunternehmen Henke-Sass, Wolf GmbH übernimmt die Zünd Präzisionsoptik AG

DSM and Firmenich have completed their EUR 35 bn merger, becoming the leading creation and innovation partner in nutrition, beauty and well-being

Alentis Therapeutics Closes USD 105m Series C Funding

BC Platforms Announces USD 20 Million Growth Financing led by Jolt Capital joins Elvaston

Versant Ventures launches Vector BioPharma with USD 30m Series A

Elvaston sells Magnolia International AG to GENUI

The Best Lawyers Awards 2023

ImmunOs Therapeutics Raises USD 74 Million Series B Financing Round

DSM and Firmenich to merge in EUR 42bn transaction, becoming the leading creation and innovation partner in nutrition, beauty and well-being

Engimmune Therapeutics raises CHF 15.5m in Seed Financing

Versant Ventures launches Cimeio Therapeutics with USD 50m Series A

kooky secures financing in the amount of EUR 6 million

Memo Therapeutics Closes Series B Financing at CHF 37m Following Oversubscribed CHF 23m Extension

Avery Dennison acquires TexTrace

Alloy Therapeutics acquires deepCDR Biologics

GlycoEra CHF 45m Series A Financing

Perconex Holding GmbH acquires Flex Suisse AG

Polyphor and EnBiotix sign merger agreement and agreement on sale of Murapavadin

Alentis Therapeutics raccoglie 67 milioni di USD in un round di finanziamento di serie B

proLogistik Holding GmbH acquisisce XELOG AG

Calibre Scientific, Inc. acquires HUBERLAB.AG

Boehringer Ingelheim: 1,18 miliardi di euro per acquisire NBE Therapeutics

Round di finanziamento di serie A da CHF 54 milioni per Noema Pharma

Synendos Therapeutics CHF 20m Series A Financing

VectivBio USD 110m Crossover Financing

Finanziamento di serie B da USD 96 milioni per Monte Rosa Therapeutics

Round di finanziamento di serie B da CHF 19 milioni per BioVersys

Versant Ventures lancia Matterhorn Biosciences

Versant Ventures lancia Bright Peak Therapeutics

Walder Wyss fornisce consulenza a BC Platforms sul finanziamento di serie C da 15 milioni di dollari e su una partnership con IQVIA per estendere l’analisi dei dati alla genomica

ImmunOs Therapeutics AG raises CHF 15m in Series A Financing

Lindsay Goldberg acquisisce Bilcare Research Group

Boehringer Ingelheim acquisisce Amal Therapeutics SA

Premio “Best Lawyers” 2020

Round di finanziamento seed per Premark Pharma GmbH

Round di finanziamento da CHF 12,5 milioni per Alentis Therapeutics SA

Precision Surfacing Solutions acquista la divisione di Meyer Burger specializzata in wafer fotovoltaici

SHS investe nella società svizzera del settore Life Science evitria SA

Cellestia Biotech SA: round di finanziamento di serie A da CHF 20 milioni

Round di finanziamento di serie A da CHF 9 milioni per TOLREMO Therapeutics SA

Nouscom AG EUR 42 Mio. Serie B Finanzierungsrunde

BC Platforms CHF10 Mio. B Runde

BioVersys CHF 5.5 Mio. Serie A Runde

Acino veräussert sein Geschäft mit transdermalen Pflastern an Luye Pharma Group Ltd.

Bayer verkauft Diabetes-Care-Geschäft

Bayer und CRISPR Therapeutics gründen Genome Editing Joint Venture

Honeywell übernimmt Aviaso

Finanzierungsrunde von CRISPR Therapeutics

Avanade erwirbt

P&I Personal & Informatik AG übernimmt Geschäftsbereich HR der Soreco AG

SVC-AG für KMU Risikokapital erwirbt Minderheitsbeteiligung an Stratpharma AG

Beschaffungsmöglichkeiten für Medizinprodukte im Lichte einer drohenden Versorgungslücke in der Schweiz

Einfuhr und Ausfuhr von Medizinprodukten in der Schwebe

§ 35 Einführung in die Grundlagen und die Systematik des schweizerischen Medizinprodukterechts